The Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic Review

Clinical Cardiology

Volumn 39, Issue 1, 2016, Pages 48-55

  Lu, Chang ^a   Filion, Kristian B ^a,b,c   Eisenberg, Mark J ^a,b,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; BIORESORBABLE SCAFFOLD; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; DRUG ELUTING CORONARY STENT; HEART DEATH; HEART INFARCTION; HUMAN; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; DEVICES; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

ABSORBABLE IMPLANTS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY DISEASE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84955372676     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22451     Document Type: Review

References (33)

1. Bourantas CV, Zhang Y, Farooq V, et al., Bioresorbable scaffolds: current evidence and ongoing clinical trials. Curr Cardiol Rep. 2012; 14: 626-634.
2. Kay IP, Wardeh AJ, Kozuma K, et al., Radioactive stents delay but do not prevent in-stent neointimal hyperplasia. Circulation. 2001; 103: 14-17.
3. McFadden EP, Stabile E, Regar E, et al., Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519-1521.
4. Hofma SH, van der Giessen WJ, van Dalen BM, et al., Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006; 27: 166-170.
5. Zhang Y, Bourantas CV, Farooq V, et al., Bioresorbable scaffolds in the treatment of coronary artery disease. Med Devices (Auckl). 2013; 6: 37-48.
6. Moher D, Liberati A, Tetzlaff J, et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264-269, W64.
7. Serruys PW, Chevalier B, Dudek D, et al., A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385: 43-54.
8. Gori T, Schulz E, Hink U, et al., Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014; 9: 1036-1041.
9. Costopoulos C, Latib A, Naganuma T, et al., Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Cathet Cardiovasc Interv. 2015; 85: E10-E15.
10. Capodanno D, Gori T, Nef H, et al., Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10: 1144-1153.
11. Kraak RP, Hassell ME, Grundeken MJ, et al., Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention. 2015; 10: 1160-1168.
12. Serruys PW, Onuma Y, Garcia-Garcia HM, et al., Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014; 9: 1271-1284.
13. Diletti R, Karanasos A, Muramatsu T, et al., Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014; 35: 777-786.
14. Onuma Y, Dudek D, Thuesen L, et al., Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013; 6: 999-1009.
15. Wiebe J, Möllmann H, Most A, et al., Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014; 103: 141-148.
16. Kajiya T, Liang M, Sharma RK, et al., Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013; 9: 501-504.
17. Abizaid A, Ribamar Costa J Jr, Bartorelli AL, et al; ABSORB EXTEND Investigators. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015; 10: 1396-1401.
18. Serruys PW, Onuma Y, Dudek D, et al., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011; 58: 1578-1588.
19. Serruys PW, Ormiston JA, Onuma Y, et al., A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373: 897-910.
20. Ormiston JA, Serruys PW, Onuma Y, et al., First serial assessment at 6 months and 2 years of the second generation of Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. 2012; 5: 620-632.
21. Finn AV, Joner M, Nakazawa G, et al., Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007; 115: 2435-2441.
22. Onuma Y, Serruys PW, Perkins LE, et al., Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010; 122: 2288-2300.
23. Bangalore S, Toklu B, Amoroso N, et al., Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013; 347: f6625.
24. Oberhauser JP, Hossainy S, Rapoza RJ,. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009; 5 (suppl F): F15-F22.
25. Okamura T, Garg S, Gutiérrez-Chico JL, et al., In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention. 2010; 5: 932-938.
26. Ormiston JA, Serruys PW, Regar E, et al., A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371: 899-907.
27. Gogas BD, Farooq V, Onuma Y, et al., The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? Hellenic J Cardiol. 2012; 53: 301-309.
28. Prabhu S, Hossainy S,. Modeling of degradation and drug release from a biodegradable stent coating. J Biomed Mater Res A. 2007; 80: 732-741.
29. Diletti R, Farooq V, Girasis C, et al., Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of Absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart. 2013; 99: 98-105.
30. Roleder T, Parma Z, Smolka G, et al., Optical coherence tomography imaging of everolimus-eluting bioresorbable vascular scaffold implanted into coronary vein graft at 3-month follow-up. Eur Heart J. 2014; 35: 2207.
31. Abbott completes enrollment of Absorb randomized clinical trials in the United States, Japan and China [press release]. Abbott Park, IL: Abbott; April 10, 2014. http://abbott.mediaroom.com/2014-04-10-Abbott-Completes-Enrollment-of-Absorb-Randomized-Clinical-Trials-in-the-United-States-Japan-and-China. Accessed: May 19, 2014.
32. Diletti R, Serruys PW, Farooq V, et al., ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design. Am Heart J. 2012; 164: 654-663.
33. Woudstra P, Grundeken MJ, Kraak RP, et al., Amsterdam Investigator-Initiated Absorb Strategy All-Comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE Prime or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design. Am Heart J. 2014; 167: 133-140.